PUOTI, Massimo
 Distribuzione geografica
Continente #
NA - Nord America 8.221
AS - Asia 3.233
EU - Europa 2.456
SA - Sud America 527
Continente sconosciuto - Info sul continente non disponibili 120
AF - Africa 68
OC - Oceania 21
Totale 14.646
Nazione #
US - Stati Uniti d'America 8.085
CN - Cina 1.213
SG - Singapore 1.066
UA - Ucraina 749
BR - Brasile 446
DE - Germania 424
HK - Hong Kong 356
FI - Finlandia 229
IT - Italia 211
GB - Regno Unito 178
FR - Francia 159
IN - India 141
VN - Vietnam 139
TR - Turchia 130
RU - Federazione Russa 118
IE - Irlanda 117
PL - Polonia 115
CA - Canada 67
BD - Bangladesh 44
SE - Svezia 41
AR - Argentina 27
ZA - Sudafrica 26
MX - Messico 24
IQ - Iraq 22
JP - Giappone 19
AU - Australia 17
BE - Belgio 16
NL - Olanda 16
PK - Pakistan 16
CO - Colombia 15
SA - Arabia Saudita 14
ES - Italia 13
EU - Europa 13
VE - Venezuela 13
EC - Ecuador 12
LT - Lituania 12
JM - Giamaica 11
UZ - Uzbekistan 11
AT - Austria 10
CH - Svizzera 9
IR - Iran 9
NG - Nigeria 8
CL - Cile 7
ID - Indonesia 7
KE - Kenya 7
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
GT - Guatemala 6
IL - Israele 6
MA - Marocco 6
HN - Honduras 5
PT - Portogallo 5
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HU - Ungheria 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
RS - Serbia 4
TN - Tunisia 4
CZ - Repubblica Ceca 3
EG - Egitto 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AL - Albania 2
BB - Barbados 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
KG - Kirghizistan 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
ET - Etiopia 1
GY - Guiana 1
HT - Haiti 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LR - Liberia 1
LY - Libia 1
MK - Macedonia 1
NO - Norvegia 1
Totale 14.532
Città #
Ashburn 957
Woodbridge 766
Fairfield 665
Jacksonville 553
Singapore 546
San Jose 510
Houston 487
Hong Kong 356
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 304
The Dalles 229
Nanjing 228
Council Bluffs 209
Princeton 193
Chandler 177
Beijing 174
Los Angeles 124
Dublin 116
Helsinki 113
Warsaw 113
Columbus 112
New York 112
Istanbul 102
Lauterbourg 98
Nanchang 90
Dearborn 80
Moscow 70
Shenyang 59
São Paulo 59
Des Moines 55
Buffalo 51
Ho Chi Minh City 50
Changsha 49
Munich 47
Shanghai 47
San Diego 46
Jinan 43
Tianjin 43
Hebei 41
Jiaxing 36
San Francisco 36
Milan 34
Lancaster 33
London 33
Brescia 32
Redondo Beach 32
Santa Clara 31
Washington 31
Chicago 29
Dallas 26
Toronto 25
Orem 23
Chennai 22
Verona 22
Hanoi 20
Kunming 20
Phoenix 20
Brooklyn 19
Tokyo 19
Charlotte 18
Hangzhou 17
Brussels 16
Lanzhou 16
Taizhou 16
Kocaeli 15
Rio de Janeiro 15
Zhengzhou 15
Brasília 14
Guangzhou 14
Atlanta 13
Johannesburg 13
Leawood 13
San Mateo 13
Norwalk 12
Stockholm 12
Denver 11
Haikou 11
Monmouth Junction 11
Boston 10
Augusta 9
Belo Horizonte 9
Campinas 9
Curitiba 9
Delhi 9
Manchester 9
Melbourne 9
Montreal 9
Ningbo 9
Nuremberg 9
Porto Alegre 9
Tashkent 9
Abuja 8
Ardabil 8
Frankfurt am Main 8
Mexico City 8
New Delhi 8
Sydney 8
Turku 8
Totale 10.037
Nome #
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 224
Use of brain MRI in manganese exposure 219
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 214
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 207
Antiretroviral drugs and liver injury. 191
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 185
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 181
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 178
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 177
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 177
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 176
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 174
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 171
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 162
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 162
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 160
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 160
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 160
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 159
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 158
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 157
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 157
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 157
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 157
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 156
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 153
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 153
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 149
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 148
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 147
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 146
Care of patients with hepatitis C and HIV co-infection. 146
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 142
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 140
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 140
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 140
Mortality for liver disease in patients with HIV infection: a cohort study 139
Polymorphic immune restoration syndrome after effective HAART 139
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 138
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 137
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 136
HIV/HCV co-infection: natural history. 133
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 133
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 132
Natural history of chronic hepatitis B in co-infected patients. 132
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 132
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 131
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 131
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 130
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 129
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 129
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 129
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 128
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 128
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 127
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 127
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 127
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 127
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 126
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 126
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 125
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 125
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 125
Management of hepatitis C in human immunodeficiency virus-infected patients. 124
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 123
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 123
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 123
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 123
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 123
HCV chronic hepatitis in patients with HIV: clinical management issues 122
The use of molecular assays in the management of viral hepatitis. 122
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 121
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 120
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 120
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 119
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 118
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 118
The burden of HIV and hepatitis C virus coinfection. 118
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 117
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 117
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 116
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 116
Impact of hepatitis C virus infection on lifestyle. 115
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 115
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 114
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 114
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 112
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 109
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 104
HCV infection: pathogenesis, clinical manifestations and therapy. 103
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 103
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 102
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 101
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 100
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 100
Pathogenesis of liver damage in HCV-HIV patients. 98
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 98
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 91
The epidemiological pattern of chronic liver diseases in acommunity undergoing voluntary screening for hepatitis B and C. 90
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 88
Totale 13.644
Categoria #
all - tutte 65.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022653 0 0 0 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.702 8 4 7 237 213 158 156 39 150 148 372 210
2025/20263.257 352 484 166 395 382 237 532 113 152 292 113 39
2026/20271.115 150 151 327 487 0 0 0 0 0 0 0 0
Totale 14.646